Aß oligomers peak in early clinical stages of Alzheimer´s disease and proceed Tau pathology
Lara Blömeke, Fabian Rehn, Victoria Kraemer‐Schulien, Janine Kutzsche, Marlene Pils, Tuyen Bujnicki, Josef Priller, Anja Schneider, Jens Wiltfang, Frank Jessen, Emrah Düzel, Katharina Buerger, Robert Perneczky, Stefan Teipel, Christoph Laske, Annika Spottke, Michael Wagner, Oliver Bannach, Dieter Willbold, Oliver Peters- Psychiatry and Mental health
- Cellular and Molecular Neuroscience
- Geriatrics and Gerontology
- Neurology (clinical)
- Developmental Neuroscience
- Health Policy
- Epidemiology
Abstract
Background
Aß oligomers are synaptotoxic and may initiate neurodegeneration in early stages of Alzheimer´s disease (AD).
Method
526 patients and controls from the DELCODE cohort were clinically diagnosed and afterwards neurobiologically classified using the ATN‐system. Aß and Tau oligomers were determined using the sFIDA technology.
Result
Within the AD continuum highest oligomer levels in CSF were detected in amyloid positive SCD and MCI. Aß oligomers outnumber in A+T‐ when compared to normal biomarker profile (A‐T‐) or full‐blown AD pathology (A+T+). APOE ε4 was associated with elevated Aß oligomer levels. No differences in Tau oligomers were found.
Conclusion
The appearance of Aß oligomers in CSF is an early event within the AD continuum precedeing the maximum of Tau pathology. Targeting Aß oligomers by disease modifying treatment in early disease stages might be crucial and is supposed to have the highest therapeutical potential in AD.